Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.

Wanquet A, Courtier F, Guille A, Carbuccia N, Garnier S, Adélaide J, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Birnbaum D, Murati A.

Leuk Lymphoma. 2019 May;60(5):1289-1293. doi: 10.1080/10428194.2018.1522437. Epub 2019 Jan 2. No abstract available.

PMID:
30601073
2.

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Lehmann-Che J, Bally C, Letouzé E, Berthier C, Yuan H, Jollivet F, Ades L, Cassinat B, Hirsch P, Pigneux A, Mozziconacci MJ, Kogan S, Fenaux P, de Thé H.

Nat Commun. 2018 May 24;9(1):2047. doi: 10.1038/s41467-018-04384-5.

3.

Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.

Venton G, Courtier F, Charbonnier A, D'incan E, Saillard C, Mohty B, Mozziconacci MJ, Birnbaum D, Murati A, Vey N, Rey J.

Am J Hematol. 2018 Mar;93(3):330-338. doi: 10.1002/ajh.24973. Epub 2017 Dec 6.

4.

JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.

De Grandis M, Bardin F, Fauriat C, Zemmour C, El-Kaoutari A, Sergé A, Granjeaud S, Pouyet L, Montersino C, Chretien AS, Mozziconacci MJ, Castellano R, Bidaut G, Boher JM, Collette Y, Mancini SJC, Vey N, Aurrand-Lions M.

Cancer Res. 2017 Dec 1;77(23):6627-6640. doi: 10.1158/0008-5472.CAN-17-1223. Epub 2017 Sep 28.

5.

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.

Cervera N, Carbuccia N, Mozziconacci MJ, Adélaïde J, Garnier S, Guille A, Murati A, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Blood Cancer J. 2017 Aug 25;7(8):e594. doi: 10.1038/bcj.2017.68. No abstract available.

6.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.

7.

Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Chaffanet M, Birnbaum D, Murati A.

Haematologica. 2017 Jan;102(1):e11-e14. doi: 10.3324/haematol.2016.152363. Epub 2016 Oct 14. No abstract available.

8.

Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Luquet I, Bidet A, Cuccuini W, Lafage-Pochitaloff M, Mozziconacci MJ, Terré C.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):535-546. Review.

PMID:
27545007
9.

Cytogenetics in the management of Philadelphia-negative myeloproliferative neoplasms: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Bilhou-Nabéra C, Bidet A, Eclache V, Lippert E, Mozziconacci MJ.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):517-523. Review.

PMID:
27477946
10.

Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Roche-Lestienne C, Boudry-Labis E, Mozziconacci MJ.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):511-515. Review.

PMID:
27477825
11.

Characterization of leukemias with ETV6-ABL1 fusion.

Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Frederik Falkenburg JH, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J.

Haematologica. 2016 Sep;101(9):1082-93. doi: 10.3324/haematol.2016.144345. Epub 2016 May 26.

12.

Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.

Latger-Cannard V, Philippe C, Bouquet A, Baccini V, Alessi MC, Ankri A, Bauters A, Bayart S, Cornillet-Lefebvre P, Daliphard S, Mozziconacci MJ, Renneville A, Ballerini P, Leverger G, Sobol H, Jonveaux P, Preudhomme C, Nurden P, Lecompte T, Favier R.

Orphanet J Rare Dis. 2016 Apr 26;11:49. doi: 10.1186/s13023-016-0432-0.

13.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S.

Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25.

14.

Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.

Antony-Debré I, Duployez N, Bucci M, Geffroy S, Micol JB, Renneville A, Boissel N, Dhédin N, Réa D, Nelken B, Berthon C, Leblanc T, Mozziconacci MJ, Favier R, Heller PG, Abdel-Wahab O, Raslova H, Latger-Cannard V, Preudhomme C.

Leukemia. 2016 Apr;30(4):999-1002. doi: 10.1038/leu.2015.236. Epub 2015 Aug 28. No abstract available.

PMID:
26316320
15.

Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.

Cervera N, Carbuccia N, Garnier S, Guille A, Adélaïde J, Murati A, Vey N, Mozziconacci MJ, Chaffanet M, Birnbaum D, Gelsi-Boyer V.

Leukemia. 2016 Apr;30(4):966-70. doi: 10.1038/leu.2015.198. Epub 2015 Jul 23. No abstract available.

PMID:
26202927
16.

A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study.

Cayuela JM, Mauté C, Fabre AL, Nibourel O, Dulucq S, Delabesse E, Villarèse P, Hayette S, Mozziconacci MJ, Macintyre E; GBMHM.

Clin Biochem. 2015 Oct;48(15):982-7. doi: 10.1016/j.clinbiochem.2015.04.004. Epub 2015 Apr 12.

PMID:
25872147
17.

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.

Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.

Oncotarget. 2015 Apr 10;6(10):8388-96.

18.

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Collette Y, Prébet T, Goubard A, Adélaïde J, Castellano R, Carbuccia N, Garnier S, Guille A, Arnoulet C, Charbonier A, Mozziconacci MJ, Birnbaum D, Chaffanet M, Vey N.

Blood Cancer J. 2015 Mar 13;5:e292. doi: 10.1038/bcj.2015.13. No abstract available.

19.

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia.

Tiberi G, Pekowska A, Oudin C, Ivey A, Autret A, Prebet T, Koubi M, Lembo F, Mozziconacci MJ, Bidaut G, Chabannon C, Grimwade D, Vey N, Spicuglia S, Calmels B, Duprez E.

Leukemia. 2015 May;29(5):1202-6. doi: 10.1038/leu.2014.339. Epub 2014 Dec 8. No abstract available.

PMID:
25482132
20.

Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.

Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D'Incan E, Charbonnier A, Blaise D, Mozziconacci MJ, Vey N.

Am J Hematol. 2015 Jan;90(1):E22-4. doi: 10.1002/ajh.23850. Epub 2014 Oct 18. No abstract available.

21.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O.

Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. No abstract available.

PMID:
25212275
22.

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.

Prebet T, Bertoli S, Delaunay J, Pigneux A, Delabesse E, Mozziconacci MJ, Bidet A, Recher C, Vey N.

Haematologica. 2014 Oct;99(10):e185-7. doi: 10.3324/haematol.2014.109827. Epub 2014 Jun 27. No abstract available.

23.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.

Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23.

PMID:
24836762
24.

Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia.

Saillard C, Etienne A, Charbonnier A, D'incan E, Rey J, Arnoulet C, Mozziconacci MJ, Blaise D, Vey N, Prebet T.

Leuk Lymphoma. 2014 Sep;55(9):2211-2. doi: 10.3109/10428194.2013.876497. Epub 2014 Jan 28. No abstract available.

PMID:
24354683
25.

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Brecqueville M, Rey J, Devillier R, Guille A, Gillet R, Adélaide J, Gelsi-Boyer V, Arnoulet C, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Murati A.

Haematologica. 2014 Jan;99(1):37-45. doi: 10.3324/haematol.2013.091454. Epub 2013 Aug 30.

26.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

27.

Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies.

Soler G, Kaltenbach S, Dobbelstein S, Broccardo C, Radford I, Mozziconacci MJ, Bernard OA, Penard-Lacronique V, Delabesse E, Romana SP.

Blood Cancer J. 2013 Jul 12;3:e124. doi: 10.1038/bcj.2013.20. No abstract available.

28.

Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature.

Chapiro E, Radford-Weiss I, Cung HA, Dastugue N, Nadal N, Taviaux S, Barin C, Struski S, Talmant P, Vandenberghe P, Mozziconacci MJ, Tigaud I, Lefebvre C, Penther D, Bastard C, Lippert E, Mugneret F, Romana S, Bernard OA, Harrison CJ, Russell LJ, Nguyen-Khac F; Groupe Francophone de Cytogénétique Hématologique.

Cancer Genet. 2013 May;206(5):162-73. doi: 10.1016/j.cancergen.2013.04.004. Epub 2013 Jul 1. Review.

PMID:
23827691
29.

Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia.

Prebet T, Carbuccia N, Raslova H, Favier R, Rey J, Arnoulet C, Vey N, Vainchenker W, Birnbaum D, Mozziconacci MJ.

Eur J Haematol. 2013 Sep;91(3):277-9. doi: 10.1111/ejh.12147. Epub 2013 Jun 28. No abstract available.

PMID:
23692290
30.

Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Prebet T, Charbonnier A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, Vey N.

Leuk Lymphoma. 2013 Jul;54(7):1538-40. doi: 10.3109/10428194.2012.744455. Epub 2012 Nov 29. No abstract available.

PMID:
23110702
31.

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, Arnoulet C, Mozziconacci MJ, Mills KI, Cross NC, Vey N, Birnbaum D.

Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506. Epub 2012 Oct 12.

32.

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblondon V; Groupe Français d'Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW); Groupe Ouest-Est d’étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS); Groupe d’Etude des Lymphomes de l’Adulte (GELA).

Haematologica. 2013 Apr;98(4):649-54. doi: 10.3324/haematol.2012.070458. Epub 2012 Oct 12.

33.

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.

Sebaa A, Ades L, Baran-Marzack F, Mozziconacci MJ, Penther D, Dobbelstein S, Stamatoullas A, Récher C, Prebet T, Moulessehoul S, Fenaux P, Eclache V.

Genes Chromosomes Cancer. 2012 Dec;51(12):1086-92. doi: 10.1002/gcc.21993. Epub 2012 Aug 30.

PMID:
22933333
34.

PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.

Borel C, Dastugue N, Cances-Lauwers V, Mozziconacci MJ, Prebet T, Vey N, Pigneux A, Lippert E, Visanica S, Legrand F, Rault JP, Taviaux S, Bastard C, Mugneret F, Collonges Rames MA, Gachard N, Talmant P, Delabesse E, Récher C.

Leuk Res. 2012 Nov;36(11):1365-9. doi: 10.1016/j.leukres.2012.07.008. Epub 2012 Aug 5.

PMID:
22871473
35.

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms.

Brecqueville M, Cervera N, Adélaïde J, Rey J, Carbuccia N, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Gelsi-Boyer V, Murati A.

Blood Cancer J. 2011 Aug;1(8):e33. doi: 10.1038/bcj.2011.31. Epub 2011 Aug 26. No abstract available.

36.

Myeloid malignancies: mutations, models and management.

Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D.

BMC Cancer. 2012 Jul 23;12:304. doi: 10.1186/1471-2407-12-304. Review.

37.

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ.

Am J Hematol. 2012 Jul;87(7):659-62. doi: 10.1002/ajh.23211. Epub 2012 Apr 25.

38.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2012 Aug;51(8):743-55. doi: 10.1002/gcc.21960. Epub 2012 Apr 9.

PMID:
22489043
39.

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D.

J Hematol Oncol. 2012 Mar 21;5:12. doi: 10.1186/1756-8722-5-12. Review.

40.

Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course.

Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L; BCGHo and the GFCH.

Ann Hematol. 2012 Jun;91(6):863-73. doi: 10.1007/s00277-011-1393-y. Epub 2011 Dec 30.

PMID:
22205151
41.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.

Duhoux FP, Ameye G, Montano-Almendras CP, Bahloula K, Mozziconacci MJ, Laibe S, Wlodarska I, Michaux L, Talmant P, Richebourg S, Lippert E, Speleman F, Herens C, Struski S, Raynaud S, Auger N, Nadal N, Rack K, Mugneret F, Tigaud I, Lafage M, Taviaux S, Roche-Lestienne C, Latinne D, Libouton JM, Demoulin JB, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO).

Br J Haematol. 2012 Jan;156(1):76-88. doi: 10.1111/j.1365-2141.2011.08918.x. Epub 2011 Nov 3.

PMID:
22050763
42.

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.

Duhoux FP, Ameye G, Lambot V, Herens C, Lambert F, Raynaud S, Wlodarska I, Michaux L, Roche-Lestienne C, Labis E, Taviaux S, Chapiro E, Nguyen-Khac F, Struski S, Dobbelstein S, Dastugue N, Lippert E, Speleman F, Van Roy N, De Weer A, Rack K, Talmant P, Richebourg S, Mugneret F, Tigaud I, Mozziconacci MJ, Laibe S, Nadal N, Terré C, Libouton JM, Decottignies A, Vikkula M, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO).

PLoS One. 2011;6(10):e26311. doi: 10.1371/journal.pone.0026311. Epub 2011 Oct 21. Erratum in: PLoS One. 2011 Dec 13;6(12). doi: 10.1371/annotation/3b5aaa87-72b6-49d3-9ec9-f4a656e12e3a. Khac, Florence Nguyen [corrected to Nguyen-Khac, Florence].

43.

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes.

Brecqueville M, Cervera N, Gelsi-Boyer V, Murati A, Adélaïde J, Chaffanet M, Rey J, Vey N, Mozziconacci MJ, Birnbaum D.

Blood Cancer J. 2011 May;1(5):e18. doi: 10.1038/bcj.2011.15. Epub 2011 May 13. No abstract available.

44.

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.

Br J Haematol. 2010 Nov;151(4):365-75. doi: 10.1111/j.1365-2141.2010.08381.x. Epub 2010 Sep 29.

PMID:
20880116
45.

Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

Tabouret E, Charbonnier A, Mozziconacci MJ, Ivanov V.

Leuk Res. 2011 Jan;35(1):136. doi: 10.1016/j.leukres.2010.08.004. Epub 2010 Sep 15. No abstract available.

PMID:
20832858
46.

Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.

Raynaud S, Carbuccia N, Colin C, Adélaïde J, Mozziconacci MJ, Metellus P, Chinot O, Birnbaum D, Chaffanet M, Figarella-Branger D.

Oncol Lett. 2010 Sep;1(5):883-884. Epub 2010 Sep 1.

47.

Alteration of cohesin genes in myeloid diseases.

Rocquain J, Gelsi-Boyer V, Adélaïde J, Murati A, Carbuccia N, Vey N, Birnbaum D, Mozziconacci MJ, Chaffanet M.

Am J Hematol. 2010 Sep;85(9):717-9. doi: 10.1002/ajh.21798.

48.

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, Gelsi-Boyer V, Mozziconacci MJ.

BMC Cancer. 2010 Aug 2;10:401. doi: 10.1186/1471-2407-10-401.

49.

Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.

Nguyen-Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M, Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F, Gachard N, Nadal N, Lippert E, Struski S, Dastugue N, Cabrol C, Bernard OA; Groupe Francophone de Cytogénétique Hématologique.

Genes Chromosomes Cancer. 2010 Oct;49(10):919-27. doi: 10.1002/gcc.20802.

PMID:
20629097
50.

Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies.

Adélaïde J, Gelsi-Boyer V, Rocquain J, Carbuccia N, Birnbaum DJ, Finetti P, Bertucci F, Mozziconacci MJ, Vey N, Birnbaum D, Chaffanet M.

Leukemia. 2010 Aug;24(8):1539-41. doi: 10.1038/leu.2010.135. Epub 2010 Jun 17. No abstract available.

PMID:
20555362

Supplemental Content

Loading ...
Support Center